The tumor microenvironment controls primary effusion lymphoma growth in vivo
about
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signalingHsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteinsKSHV targets multiple leukocyte lineages during long-term productive infection in NOD/SCID mice.Non-human primate model of Kaposi's sarcoma-associated herpesvirus infectionIncreased tumorigenicity of cells carrying recombinant human herpesvirus 8.Zidovudine-based lytic-inducing chemotherapy for Epstein-Barr virus-related lymphomas.Efficacy of bortezomib in a direct xenograft model of primary effusion lymphomaViral profiling identifies multiple subtypes of Kaposi's sarcoma.The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma.Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma.Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies.Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesisTumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.Phosphatase and tensin homolog on chromosome 10 is phosphorylated in primary effusion lymphoma and Kaposi's sarcoma.Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas.Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma.Gene alteration and precursor and mature microRNA transcription changes contribute to the miRNA signature of primary effusion lymphoma.Kaposi's sarcoma and its associated herpesvirus.mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma.CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.Tumor suppressor microRNAs are underrepresented in primary effusion lymphoma and Kaposi sarcomaProductively infected murine Kaposi's sarcoma-like tumors define new animal models for studying and targeting KSHV oncogenesis and replication.Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expressionRecent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis.Herpesviruses shape tumour microenvironment through exosomal transfer of viral microRNAs.Establishment of a CD4-positive cell line from an AIDS-related primary effusion lymphoma.Diagnosis and Treatment of Kaposi Sarcoma.Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo.In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: a cell and animal model of virally induced Kaposi's sarcoma.FUS Negatively Regulates Kaposi's Sarcoma-Associated Herpesvirus Gene Expression
P2860
Q24673299-734E140D-88BD-4ADB-AC8A-A502D65640F9Q28485399-C3C3C2E4-A94E-4609-A8B6-17615E84F4A7Q30440843-8D39EE13-5295-4D40-8BDB-2B94CA1025D4Q33508240-EA323AB7-8146-4C2C-B74B-08FBF7DD4AD0Q33585787-DFAAE5C9-4A62-47F1-956F-D6F1C0A2575BQ34053519-1C00BF7D-9584-4581-9951-EF2531B2D971Q34059058-CEF65D54-28D6-4FB7-9166-CD3C04E875ACQ34237734-BB04D72B-70D7-474E-B8BA-8F0C8BD9DBA9Q34391203-CB1A5629-CBE2-438A-95F3-D447EC153DCCQ34480968-98D1C2F9-E949-4BCD-A402-EEC4BE55372DQ34845533-6607709E-C8FD-4E89-9FEB-C91A12A201AAQ35127940-9E3849F6-B130-4EB8-BCEF-00851A910A49Q35172518-57B41016-F6C7-46BE-AC70-8339A103A3D0Q35235757-6FF08799-080B-4803-8635-DE7839C36ABEQ35635426-CEA9A545-14F8-4BCF-900B-F4F5BB904AA8Q35664106-EAF82642-8B1D-4CBA-94A5-BCB2472FD282Q36334405-F104657A-3E9F-4424-BCC3-D05D38BB3E06Q36445916-E04C45BA-41DD-4615-8E85-D29205EF9377Q36487309-3E71D595-648D-4E31-9A6C-EACA19E92C4CQ36745445-5EBFB412-2581-4625-AA25-4E26724B65F0Q36890993-D6D29BC6-2932-46FA-B034-035B54A91B9BQ37098844-A1B7B2F4-537A-4AA7-ADFF-EF56CB725FC0Q37237479-81E7B1C0-9EA2-4816-8958-653295AB7B73Q37525707-EE57F828-360D-4E39-A2CC-798A6462C3D8Q38319392-7FA1C928-EB01-4CBA-A28D-057A56D5EA47Q38449592-86762922-20CE-48C6-B495-22CED2A50926Q38610039-9235D342-26D5-4441-B7DD-C05896B008BFQ39162733-68198F9E-D99B-49EE-9F37-F4B09239D1A9Q39190555-3D606375-706E-474C-81ED-BAF2C66D0FD0Q40287215-B52CA8F9-802E-48A2-BE0E-D89452D8875AQ41839438-E4B6330D-662A-4350-9017-6213AFAC0AB3Q57029061-FA1E6956-A5AA-4EE0-B99B-C15BC3776CEC
P2860
The tumor microenvironment controls primary effusion lymphoma growth in vivo
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@ast
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@en
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@nl
type
label
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@ast
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@en
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@nl
prefLabel
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@ast
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@en
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@nl
P2093
P1433
P1476
The tumor microenvironment controls primary effusion lymphoma growth in vivo
@en
P2093
Dirk P Dittmer
James F Papin
Joseph H Jeong
Michelle R Staudt
Rebecca Hines-Boykin
Yogita Kanan
P304
P356
10.1158/0008-5472.CAN-03-3835
P407
P577
2004-07-15T00:00:00Z